Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.7 |
mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | YL54 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.7 |
mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.0093 | 0.7 |
mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |